News

Angeion Corporation to Participate in Two Upcoming Industry Trade Shows

ST. PAUL, Minn.-(Business Wire)-October 3, 2008 - Angeion Corporation (NASDAQ: ANGN) today announced that it is participating in two upcoming industry trade shows. The Company will be exhibiting at the 2008 European Respiratory Society’s (ERS) 8^th Annual Congress Oct. 4-8 in Berlin, Germany. Angeion also will participate in MEDICA 2008, Nov. 19-22, in Düsseldorf, Germany. At both events, the Company will feature its flagship line of systems for diagnosing cardiorespiratory and cardiopulmonary conditions, such as chronic obstructive pulmonary disease (COPD).

“We are excited about exhibiting at this year’s ERS Annual Congress and MEDICA 2008. Both events give us an opportunity to showcase our revolutionary products in an interactive venue,” said Rodney A. Young, President and Chief Executive Officer. “ERS is Europe’s biggest annual scientific gathering in respiratory medicine, and MEDICA is the largest industry trade fair outside of North America for U.S. and Canadian companies. We look forward to the opportunities at these events and sharing our technology with an international community of experts and thought leaders.”

ERS 8^th Annual Congress

The ERS brings together many of the world's top respiratory researchers and clinicians to hear the latest advances in clinical diagnosis and treatment. ERS is Europe's biggest annual scientific gathering in respiratory medicine, with more than 17,000 participants each year. It aims to provide a platform for important improvements in the treatment of lung diseases. Full details of ERS may be viewed on the ERS website at http://dev.ersnet.org/415-general-information.htm. Angeion will be featured at Stand No. Hall 3/3.32.

MEDICA 2008

At the 2008 MEDICA event in Berlin, more than 135,000 visitors are expected to learn about the current and future trends in in-patient and out-patient care. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the European medical trade—and the strongest medical industry trade fair outside of North American for U.S. and Canadian exhibitors. Angeion will be featured at booth 11A55. To learn more about this event visit: http://www.medica.de/ and click on the English-speaking option.

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Our actual results may differ materially depending on a variety of factors including: (i) our ability to successfully operate our business including our ability to develop, improve, and update our cardiorespiratory diagnostic products and successfully sell these products into existing and new markets, (ii) our ability to achieve constant margins for products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers, (iii) our ability to effectively manufacture and ship products in required quantities to meet customer demands, (iv) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products, (v) our ability to protect our intellectual property, (vi) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures, and (vii) our dependence on third-party vendors.

Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company’s Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2007.

Send this news item to a friend.

Print This Page